5409372025-10-012025-12-315409372025-04-012025-12-315409372025-10-012025-12-31in-capmkt:OtherExpenses1Member5409372025-10-012025-12-31in-capmkt:OtherExpenses2Member5409372025-10-012025-12-31in-capmkt:OtherExpenses3Member5409372025-04-012025-12-31in-capmkt:OtherExpenses1Member5409372025-04-012025-12-31in-capmkt:OtherExpenses2Member5409372025-04-012025-12-31in-capmkt:OtherExpenses3Member5409372025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15409372025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25409372025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15409372025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss2iso4217:INRxbrli:pureiso4217:INRxbrli:shares540937MEDICONOTLISTEDINE630Y01024MEDICO REMEDIES LIMITEDMain BoardEquity2025-04-012026-03-312026-02-122026-02-07INRLakhsQuarterlyThird quarterSingle segmentmanufacturer and exporter of pharmaceutical formulations2026-02-1217:00:002026-02-1217:30:00Not applicablefalsefalseNot Applicable2025-10-012025-12-31UnauditedStandalone5868290006768000593597000361844000221470005709100021292000386300079020008113400055527300038324000038324000860000010000009600000028724000000028724000120002873600016596800020.350.35000.350.3500.18640.1864 <BR> Notes: <BR> 1. The above unaudited standalone financial results of the company were reviewed and recommended by the audit committee on February 12, 2026 and subsequently approved by the Board of Directors at its meeting held on February 12, 2026. The review report has been filed with stock exchange and is available on the Company’s website. <BR> <BR> 2. The figures for the quarter ended on 31st December 2025 are balancing figures between the reviewed figures for the quarter ended 30th September 2025 and reviewed year to date figures upto nine months ended 31st December 2025. <BR> <BR> 3. The standalone financial results for the quarter ended on 31st December, 2025 have been subjected to Limited Review by statutory auditors of the company and the statutory auditors have issued unmodified report on unaudited financial results. <BR> <BR> 4. The above financial results have been prepared as per IND AS and all standards and requirements of IND AS are complied with by the company. <BR> <BR> 5. Medico Remedies Limited is a pharmaceutical formulation manufacturing company and the management reviews the performance of the company as a single operating segment in accordance with IND-AS 108 “Operating Segments” notified pursuant to Companies (Accounting Standard) Rules, 2015. Accordingly, no segment information/segment reporting has been furnished within. Details of geographical segments are disclosed below: <BR> PARTICULARS QE 31.12.2025 QE 30.09.2025 <BR> Amount (Rs. In Lakh) Amount (Rs. In Lakh) <BR> 1)Sales of products within India 689.73 542.92 <BR> 2)Sales of products Outside India 5156.033 4675.40 <BR> Sub- Total 5845.77 5218.32 <BR> <BR> 6. Previous periods figures have been regrouped / reclassified where required to make them compatible with the figures of current periods. <BR> <BR> 7. The company does not have any subsidiary/associate/joint venture company as on 31st December 2025. <BR> <BR> 8. The result for the quarter ended December 31, 2025 is available on the BSE Limited website (URL: www.bseindia.com), NSE Limited website (URL: www.nseindia.com) and on the Company’s website (URL: www.medicoremedies.com) <BR> <BR> For and on behalf of the board, <BR> For Medico Remedies Limited <BR> <BR> <BR> Rishit Mehta Harshit Mehta <BR> Whole Time Director Managing Director <BR> DIN: 07121224 DIN:05144280 <BR> Place: Mumbai Place: Mumbai <BR> Date: February 12, 2026 Date: February 12, 2026 <BR> 2025-04-012025-12-31UnauditedStandalone1495696000305970001526293000108242800039573000-30880005642700090240002292800022159700014288890009740400009740400021700000311800024818000072586000000072586000360007262200016596800020.870.87000.870.8700.20530.2053Manufacturing Expenses39879000Selling and Distribustion Expenses23176000Other Business Administrative Expenses18079000Manufacturing Expenses119144000Selling and Distribustion Expenses58310000Other Business Administrative Expenses44143000Remeasurement of defined benefit plan16000Income tax related to items no (i) above-400012000Remeasurement of defined benefit plan48000Income tax related to items no (i) above-120003600000001200036000